Results 91 to 100 of about 283,019 (191)

Brain metastasis-associated cancer fibroblasts drive tumor progression and therapeutic resistance through IL26 and CX3CL1 signaling in non-small-cell lung cancer

Experimental Hematology & Oncology
Brain metastases (BM) from non-small cell lung cancer (NSCLC) represent a significant clinical challenge, characterized by poor prognosis and treatment resistance.
S. M. Abdus Salam, Eshrat Jahan, Eun-Jung Ahn, Sung Sun Kim, Yeong Jin Kim, Sue Jee Park, Tae-Young Jung, In-Young Kim, Shin Jung, Roo Ji Lee, Jae-Hyuk Lee, Joon Haeng Rhee, Kyung Keun Kim, Min-Hee Yi, Kyung-Hwa Lee, Kyung-Sub Moon   +15 more
doaj   +1 more source

Loss of the PTCH1 tumor suppressor defines a new subset of plexiform fibromyxoma. [PDF]

, 2019
BackgroundPlexiform fibromyxoma (PF) is a rare gastric tumor often confused with gastrointestinal stromal tumor. These so-called "benign" tumors often present with upper GI bleeding and gastric outlet obstruction.
Banerjee, Sudeep, Burgoyne, Adam M, Corless, Christopher L, Davis, Jessica L, Miettinen, Markku M, Noh, Sangkyu, Sicklick, Jason K, Tang, Chih-Min, Ustoy, Rowan, Yebra, Mayra   +9 more
core   +1 more source

Revolutionizing precision medicine in oral squamous cell carcinoma: Harnessing 3D in vitro models for translation

Oral Oncology Reports
Oral squamous cell carcinoma (OSCC) is a highly aggressive neoplasm of the surface epithelium that arises from the mucosal lining of the mouth. The poor prognosis can be attributed to the complex tumor microenvironment (TME) in OSCC, which is crucial for
Nitesh Buldak, Vishnu Priya Veeraraghavan, Ullas Mony   +2 more
doaj   +1 more source

Iatrogenic Alterations of Immunologic Surveillance in Man and Their Influence on Malignancy [PDF]

, 1971
Agosin M., Albert D., Alford T. C, Allison A. C, Alpert E., Alpert M. E., Anigsten L., Bach F. H., Baserga R., Bekkum D. W., Berman C., Bortin M. M., Bremberg S., Burnet F. M., Burnet F. M., Burnet F. M., Burnet F. M., Casey T. P., Davis R. C., Dent P. B., Deodhar S. D., Doak P. B., Doll R., Epstein R. B., Fisher E. R., Foley E. J., Foley E. J., Fortner J. G., Grant G. A., Gustafson E. G., Hellman K., Hirsch M. S., Huber J., Immunology and Cancer, Isojima S., Jensen C O., Kay S., Law L. W., MacLean L. D., Mandel M.A., Marchioro T. L., Martin D. C, Martinez C, Mathe G., Mathe G., McIntosh D. A., McKhann C. F., Miller J. F. A. P., Moore G. E., Muizniks H. W., Page A. R., Penn I., Penn I., Penn I., Penn I., Prehn R. T., Pritzker K. P. H., Rabbat A. G., Santos G. W., Santos G. W., Schwartz R., Simmons R. L., Sjogren H. O., Snell G. D., Southam C. M., Speck B., Starzl T. E., Starzl T. E., Starzl T. E., Starzl T. E., Starzl T. E., Starzl T. E., Starzl T. E., Starzl T. E., Starzl T. E., Starzl T. E., Tallent M. B., Thomas L., Toolan H.W., Tunner W. S., Tyler A., Vredevoe D. L., Weiler E., Wilson R. E., Zukoski C. F., Zukoski C. F.   +85 more
core   +1 more source

Advances in Targeted Drug Resistance Associated with Dysregulation of Lipid Metabolism in Hepatocellular Carcinoma

Journal of Hepatocellular Carcinoma
Xiaoju Huang,1– 3 Mengmeng Wang,1– 3 Dan Zhang,1– 3 Chen Zhang,4 Pian Liu1– 3 1Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, People’s Republic of China; 2Institute of Radiation ...
Huang X, Wang M, Zhang D, Zhang C, Liu P
doaj  

Beyond Oncogenes: Selectively Targeting Whole-Tumor Cell Growth Regulation. [PDF]

Drug Des Devel Ther
Qin A.
europepmc   +1 more source

Retraction Note: RNA interferences targeting the Fanconi anemia/BRCA pathway upstream genes reverse cisplatin resistance in drug-resistant lung cancer cells. [PDF]

J Biomed Sci
Dai CH, Li J, Chen P, Jiang HG, Wu M, Chen YC.   +5 more
europepmc   +1 more source

Rituximab synergizes with hydroxyurea or vincristine in the killing of Ramos Burkitt's lymphoma B cell line [PDF]

, 2014
Abulayha, Abdulmunem, Bredan, Amin, Deyab, Mohamed, Elbanani, Abdulrhman, Geriani, Hajer, Lamami, Yosra, Tabal, Salah   +6 more
core   +2 more sources

Growth rate-driven modelling suggests that phenotypic adaptation drives drug resistance in BRAFV600E-mutant melanoma. [PDF]

Commun Biol
Hamis S, Browning AP, Jenner AL, Villa C, Maini PK, Cassidy T.   +5 more
europepmc   +1 more source

Genome-Wide CRISPR Screens Identify ABCG2-Mediated Drug Resistance to the Threonine Tyrosine Kinase (TTK) Inhibitor CFI-402257 in Breast Cancer. [PDF]

Int J Mol Sci
Thu KL, Jafari S, Silvester J, Cruickshank J, Soria-Bretones I, Hodgson K, Tobin C, Haight J, Lau APY, Bray T, Wakeham D, Bray MR, Mak TW, Cescon DW.   +13 more
europepmc   +1 more source